Vienna, Austria, April 29, 2009- Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies in the indications of virology and immunology, announced today that it has been granted European Patent No. 0001842546, entitled ‘Antiviral polymer’ by the European Patent Office. The patent, which was granted in March, covers the use of a specific polymer for the prophylactic and therapeutic treatment of rhinovirus infections.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “We are delighted that this first patent has been granted. This is the first of several patent applications that were filed in order to protect our intellectual property around products for the treatment of respiratory viruses.”
Marinomed has a pipeline of natural, mainly marine derived, compounds, for the treatment of respiratory illnesses and immunological disorders. The Company’s first product, the anti-viral nasal spray COLDAMARIS prophylactic which contains Carragelose®, was launched in 2008 for the prevention of and treatment of the common cold and viral-induced respiratory infections.
About Marinomed Biotechnologie GmbH
Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies based on natural products against infectious diseases and immunological based disorders. The Company has an assay platform and marine extract library for the discovery of novel natural products. Its first product the anti-viral nasal spray COLDAMARIS prophylactic, which contains the marine derived compound Carragelose®, was launched in 2008 for the treatment of and protection against the common cold and viral-induced respiratory infections. Marinomed has additional products in development for the treatment of type I allergy, autoimmune diseases and influenza as well as for pandemic preparedness. Marinomed Biotechnologie GmbH is a spin-off company of the Veterinary University Vienna and is located in Vienna, Austria. For further information please visit the website at www.marinomed.com
